Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations

Cardiology

Volumn 94, Issue 2, 2000, Pages 127-128

  Oldemeyer, J Bradley ^a   Lund, Richard J ^a   Koch, Matt ^a   Meares, A John ^a   Dunlay, Robert ^a,b  

^a CREIGHTON UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

Acute renal failure; Fibrate; Rhabdomyolysis; Statin

Indexed keywords

FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; PRAVASTATIN; SIMVASTATIN; STATIN;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DRUG TOLERANCE; ENZYME ANALYSIS; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; MALE; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK FACTOR; TREATMENT PLANNING;

AGED; ANTILIPEMIC AGENTS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, ACUTE; MALE; PRAVASTATIN; PROCETOFEN; RHABDOMYOLYSIS; SIMVASTATIN;

EID: 0034487393     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047304     Document Type: Article

References (3)

1. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia
2. Biological myolysis during combined fenofibrate-pravastatin therapy
3. Long-term efficacy and safety of fenofibrate and a statin the treatment of combined hyperlipidemia